Recent studies into retatrutide, a dual GIP and GLP-1 agonist , are revealing encouraging efficacy for metabolic therapy. Early human assessments have indicated substantial decreases in body mass and improvements in related health markers , particularly for individuals with excess weight. Planned here pursuits concentrate on assessing the long-term